Conditions: Plaque Psoriasis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 29
Healthy volunteers: no

Brief summary:
12 weeks open label with Otezla® and NUVB, followed by 6 month double blind Otezla® (apremilast) or placebo to subjects who obtain PASI 75 at week 12 of phototherapy

Detailed description:
Primary Objective: To evaluate the effectiveness of Otezla (apremilast®) in promoting maintenance of response in those subjects who obtained PASI-75 at week 12 of phototherapy.

Arms:
arm 1: apremilast 30mg bid for 12 weeks.followed by apremilast 30 mg bid for 24 weeks arm 2: apremilast 30mg bid for 12 weeks followed by placebo bid for 24 weeks

Interventions: intervention 1: apremilast
Intervention descriptions: intervention 1: None

Protocol document: